The importance of glucose‐dependent insulinotropic polypeptide receptor activation for the effects of tirzepatide
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Tirzepatide is a unimolecular co‐agonist of the glucagon‐like peptide‐1 (GLP‐1) and glucose‐dependent insulinotropic polypeptide (GIP) receptors recently approved for the treatment of type 2 diabetes by the US Food and Drug Administration and the European Medicine Agency. Tirzepatide treatment results in an unprecedented improvement of glycaemic control and lowering of body weight, but the contribution of the GIP receptor‐activating component of tirzepatide to these effects is uncertain. In this review, we present the current knowledge about the physiological roles of the incretin hormones GLP‐1 and GIP, their receptors, and previous results of co‐targeting the two incretin hormone receptors in humans. We also analyse the molecular pharmacological, preclinical and clinical effects of tirzepatide to discuss the role of GIP receptor activation for the clinical effects of tirzepatide. Based on the available literature on the combination of GLP‐1 and GIP receptor activation, tirzepatide does not seem to have a classical co‐activating mode of action in humans. Rather, in vitro studies of the human GLP‐1 and GIP receptors reveal a biased GLP‐1 receptor activation profile and GIP receptor downregulation. Therefore, we propose three hypotheses for the mode of action of tirzepatide, which can be addressed in future, elaborate clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838 · cited 2×
“For all phase 2 17,18 and phase 3 studies of tirzepatide, 19 – 26 reported adverse events have been dominated by mild to moderate, transient, dose-dependent gastrointestinal effects (nausea, diarrhoea and vomiting), very similar to those observed during treatment with GLP-1 receptor agonists.”
BackgroundResultFredriksson, R., Lagerström, M. C., Lundin, L.-G., & Schiöth, H. B. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.6.1256 · Cited by 2,941
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., & Brown, K. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107519 · Cited by 2,096
A Placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis
Newsome, P. N., Buchholtz, K., Cusi, K., Linder, M., Okanoue, T., Ratziu, V., Sanyal, A. J., Sejling, A.-S., & Harrison, S. A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2028395 · Cited by 2,039 · cited 1×
“13 GLP-1 receptor agonist treatment results in an increase in heart rate by a few beats per minute with some variation throughout the day, presumably because of direct activation of cardiovascular GLP-1 receptors.”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationGLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647 · cited 2×
“71 A 6-week continuous GLP-1 infusion improved insulin sensitivity compared with placebo, but the improvement was probably attributable to the concomitant weight loss.”
BackgroundSelf-citationSattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 3×
“11 Because of potential beneficial effects (such as anti-inflammation) of GLP-1 receptor agonism in several organs including the central nervous system, novel indications (e.g. Alzheimer's disease, 12 non-alcoholic fatty liver disease, 13 heart failure with preserved ejection fraction 14 and bile…”
BackgroundInfluential9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s009 · Cited by 1,555
Zander, M., Madsbad, S., Madsen, J. L., & Holst, J. J. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07952-7 · Cited by 1,297 · cited 1×
“72 For GIP, the insulino-tropic effect is severely reduced in patients with type 2 diabetes, 73 – 75 but to a limited extent restorable by normalization of plasma glucose (2-4 weeks).”
BackgroundSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 2×
“4 However, the insulinotropic effect of intravenous GIP infusions was found to be severely reduced or even absent in patients with type 2 diabetes, 4 – 6 in whom GIP also turned out to stimulate glucagon secretion and impair postprandial glucose tolerance.”
BackgroundSelf-citationStructure and dynamics of GPCR signaling complexes
Hilger, D., Masureel, M., & Kobilka, B. K. (2018) · Nature Structural & Molecular Biology · doi:10.1038/s41594-017-0011-7 · Cited by 969 · cited 1×
“53 Because of this receptor desensitization following receptor activation, agonists of the GIP receptor may in some cases act as functional antagonists.”
BackgroundInhibition of gastric inhibitory polypeptide signaling prevents obesity
Miyawaki, K., Yamada, Y., Ban, N., Ihara, Y., Tsukiyama, K., Zhou, H., Fujimoto, S., Oku, A., Tsuda, K., Toyokuni, S., et al. (2002) · Nature Medicine · doi:10.1038/nm727 · Cited by 963 · cited 2×
“7 This, combined with rodent data pointing to GIP as an obesogenic hormone, 8 for many years dampened the interest in pursuing GIP receptor activation as a strategy for the treatment of type 2 diabetes and obesity.”
BackgroundSelf-citationIncretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Self-citationCoskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 2×
“16,97,105 However, it is a biased agonist of the GLP-1 receptor because it does not recruit beta-arrestin to the same extent as GLP-1, but still activates the cAMP pathway.”
BackgroundSTIMULATION OF INSULIN SECRETION BY GASTRIC INHIBITORY POLYPEPTIDE IN MAN. 1
Dupre, J., Ross, S. A., Watson, D., & Brown, J. C. (1973) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-37-5-826 · Cited by 860
Frias, J. P., Nauck, M. A., Van, J., Kutner, M. E., Cui, X., Benson, C., Urva, S., Gimeno, R. E., Milicevic, Z., Robins, D., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)32260-8 · Cited by 815 · cited 2×
“For all phase 2 17,18 and phase 3 studies of tirzepatide, 19 – 26 reported adverse events have been dominated by mild to moderate, transient, dose-dependent gastrointestinal effects (nausea, diarrhoea and vomiting), very similar to those observed during treatment with GLP-1 receptor agonists.”
BackgroundResultUnimolecular Dual Incretins Maximize Metabolic Benefits in Rodents, Monkeys, and Humans
Finan, B., Ma, T., Ottaway, N., Müller, T. D., Habegger, K. M., Heppner, K. M., Kirchner, H., Holland, J., Hembree, J., Raver, C., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3007218 · Cited by 696 · cited 1×
“96,114 NNC0090-2746, therefore, activates both the GLP-1 and the GIP receptor at lower concentrations than tirzepatide.”
BackgroundLudvik, B., Giorgino, F., Jódar, E., Frias, J. P., Fernández Landó, L., Brown, K., Bray, R., & Rodríguez, Á. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01443-4 · Cited by 639
Dahl, D., Onishi, Y., Norwood, P., Huh, R., Bray, R., Patel, H., & Rodríguez, Á. (2022) · JAMA · doi:10.1001/jama.2022.0078 · Cited by 597
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 8×
“16 The impaired arrestin recruitment also leads to enhanced insulin secretion.”
BackgroundInfluentialSelf-citationT., V., T., K., S., M., & J., H. (2002) · Diabetologia · doi:10.1007/s00125-002-0878-6 · Cited by 518
Højberg, P. V., Vilsbøll, T., Rabøl, R., Knop, F. K., Bache, M., Krarup, T., Holst, J. J., & Madsbad, S. (2009) · Diabetologia · doi:10.1007/s00125-008-1195-5 · Cited by 414
Self-citationBettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 1×
“102 Likewise, the heart rate is increased by 5-7 beats per minute, as was also observed for GLP-1 receptor agonists.”
BackgroundSelf-citationGlucose-Dependent Insulinotropic Polypeptide
Christensen, M., Vedtofte, L., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2011) · Diabetes · doi:10.2337/db11-0979 · Cited by 353
Self-citationEffects of GLP-1 on appetite and weight
Shah, M., & Vella, A. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9289-5 · Cited by 352
Tirzepatide cardiovascular event risk assessment: A pre-specified meta-analysis
Sattar, N., McGuire, D. K., Pavo, I., Weerakkody, G. J., Nishiyama, H., Wiese, R. J., & Zoungas, S. (2022) · Nature Medicine · doi:10.1038/s41591-022-01707-4 · Cited by 346 · cited 1×
“Based on the completed trials in type 2 diabetes, a cardiovascular risk assessment also favours tirzepatide, 28 but these effects will be addressed by a cardiovascular outcome trial (SURPASS-CVOT) in type 2 diabetes, with completion expected in 2024.”
BackgroundFrias, J. P., Bastyr, E. J., Vignati, L., Tschöp, M. H., Schmitt, C., Owen, K., Christensen, R. H., & DiMarchi, R. D. (2017) · Cell Metabolism · doi:10.1016/j.cmet.2017.07.011 · Cited by 321 · cited 1×
“96,114 NNC0090-2746, therefore, activates both the GLP-1 and the GIP receptor at lower concentrations than tirzepatide.”
BackgroundGLP-1 Receptor Expression Within the Human Heart
Baggio, L. L., Yusta, B., Mulvihill, E. E., Cao, X., Streutker, C. J., Butany, J., Cappola, T. P., Margulies, K. B., & Drucker, D. J. (2018) · Endocrinology · doi:10.1210/en.2018-00004 · Cited by 312
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304 · cited 1×
“87,88 Based on major cardiovascular outcome trials, GLP-1 receptor agonists reduce the risk of cardiovascular mortality, all-cause mortality and stroke.”
BackgroundCirculation and Degradation of GIP and GLP-1
Deacon, C. F. (2004) · Hormone and Metabolic Research · doi:10.1055/s-2004-826160 · Cited by 299
Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00085-7 · Cited by 268
Giugliano, D., Scappaticcio, L., Longo, M., Caruso, P., Maiorino, M. I., Bellastella, G., Ceriello, A., Chiodini, P., & Esposito, K. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01366-8 · Cited by 263
GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice
Samms, R. J., Christe, M. E., Collins, K. A. L., Pirro, V., Droz, B. A., Holland, A. K., Friedrich, J. L., Wojnicki, S., Konkol, D. L., Cosgrove, R., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci146353 · Cited by 256
The incretin system in healthy humans: The role of GIP and GLP-1
Holst, J. J. (2019) · Metabolism · doi:10.1016/j.metabol.2019.04.014 · Cited by 248
Self-citationKillion, E. A., Wang, J., Yie, J., Shi, S. D.-H., Bates, D., Min, X., Komorowski, R., Hager, T., Deng, L., Atangan, L., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat3392 · Cited by 237 · cited 1×
“…combination approaches (e.g. combinations of GLP-1 and GIP analogues, or GLP-1 and amylin analogues, 132 or GLP-1 analogues and GIP receptor antagonists 58,121,122 ), where the dose ratios could be easily adjusted according to personalized needs, such as beneficial effects versus adverse effects.”
BackgroundInagaki, N., Takeuchi, M., Oura, T., Imaoka, T., & Seino, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00188-7 · Cited by 226
Frias, J. P., Nauck, M. A., Van, J., Benson, C., Bray, R., Cui, X., Milicevic, Z., Urva, S., Haupt, A., & Robins, D. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13979 · Cited by 208
Mentis, N., Vardarli, I., Köthe, L. D., Holst, J. J., Deacon, C. F., Theodorakis, M., Meier, J. J., & Nauck, M. A. (2011) · Diabetes · doi:10.2337/db10-1332 · Cited by 197
Self-citationBray, J. J. H., Foster‐Davies, H., Salem, A., Hoole, A. L., Obaid, D. R., Halcox, J. P. J., & Stephens, J. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14399 · Cited by 194 · cited 1×
“90 The aforementioned 6-day continuous subcutaneous infusion of GIP in patients with type 1 diabetes resulted in a 12.6% ± 4.2% increase in hepatic lipid content compared with placebo, consistent with earlier proposals of the involvement of GIP in the lipid metabolism.”
ResultInfluentialGasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes · doi:10.2337/db18-1123 · Cited by 193
Self-citationFrías, J. P., Auerbach, P., Bajaj, H. S., Fukushima, Y., Lingvay, I., Macura, S., Søndergaard, A. L., Tankova, T. I., Tentolouris, N., & Buse, J. B. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00174-1 · Cited by 188
Edholm, T., Degerblad, M., Grybäck, P., Hilsted, L., Holst, J. J., Jacobsson, H., Efendic, S., Schmidt, P. T., & Hellström, P. M. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2010.01554.x · Cited by 164 · cited 1×
“3,61,62 Also, pharmacologically, compounds targeting the human GIP receptor differ when evaluated on the murine GIP receptor; for example, human GIP 1 – 42 is only a”
MethodSelf-citationNext generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Knerr, P. J., Mowery, S. A., Douros, J. D., Premdjee, B., Hjøllund, K. R., He, Y., Kruse Hansen, A. M., Olsen, A. K., Perez-Tilve, D., DiMarchi, R. D., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101533 · Cited by 152
Killion, E. A., Chen, M., Falsey, J. R., Sivits, G., Hager, T., Atangan, L., Helmering, J., Lee, J., Li, H., Wu, B., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18751-8 · Cited by 151
Zhao, F., Zhou, Q., Cong, Z., Hang, K., Zou, X., Zhang, C., Chen, Y., Dai, A., Liang, A., Ming, Q., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28683-0 · Cited by 149
Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia · doi:10.1007/s00125-018-4810-0 · Cited by 142 · cited 4×
“3,61,62 Also, pharmacologically, compounds targeting the human GIP receptor differ when evaluated on the murine GIP receptor; for example, human GIP 1 – 42 is only a”
BackgroundMethodInfluentialSelf-citationVaccination against GIP for the Treatment of Obesity
Fulurija, A., Lutz, T. A., Sladko, K., Osto, M., Wielinga, P. Y., Bachmann, M. F., & Saudan, P. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003163 · Cited by 136
Asmar, M., Asmar, A., Simonsen, L., Gasbjerg, L. S., Sparre-Ulrich, A. H., Rosenkilde, M. M., Hartmann, B., Dela, F., Holst, J. J., & Bülow, J. (2017) · Diabetes · doi:10.2337/db17-0480 · Cited by 132 · cited 1×
“45 The mesenteric blood flow is also increased during GIP administration 46 and this might be connected to the increase in heart rate observed following GIP administration.”
BackgroundSelf-citationKadowaki, T., Chin, R., Ozeki, A., Imaoka, T., & Ogawa, Y. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00187-5 · Cited by 131
The incretin co-agonist tirzepatide requires GIPR for hormone secretion from human islets
El, K., Douros, J. D., Willard, F. S., Novikoff, A., Sargsyan, A., Perez-Tilve, D., Wainscott, D. B., Yang, B., Chen, A., Wothe, D., et al. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00811-0 · Cited by 118 · cited 1×
“57,63 The species differences may preclude relevant mechanistic conclusions based on preclinical studies.”
BackgroundGögebakan, Ö., Osterhoff, M. A., Schüler, R., Pivovarova, O., Kruse, M., Seltmann, A.-C., Mosig, A. S., Rudovich, N., Nauck, M., & Pfeiffer, A. F. H. (2015) · Diabetologia · doi:10.1007/s00125-015-3618-4 · Cited by 95
Tirzepatide induces a thermogenic-like amino acid signature in brown adipose tissue
Samms, R. J., Zhang, G., He, W., Ilkayeva, O., Droz, B. A., Bauer, S. M., Stutsman, C., Pirro, V., Collins, K. A., Furber, E. C., et al. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101550 · Cited by 93 · cited 2×
“56,57 Thus, the actions of murine GIP in mice seem to differ from those of human GIP in humans, with murine GIP possibly being involved in both energy expenditure, inflammation, cardio-vascular functions, antiemetic mechanisms and appetite regulation after longer treatment periods.”
BackgroundLu, S.-C., Chen, M., Atangan, L., Killion, E. A., Komorowski, R., Cheng, Y., Netirojjanakul, C., Falsey, J. R., Stolina, M., Dwyer, D., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100263 · Cited by 91 · cited 1×
“…combination approaches (e.g. combinations of GLP-1 and GIP analogues, or GLP-1 and amylin analogues, 132 or GLP-1 analogues and GIP receptor antagonists 58,121,122 ), where the dose ratios could be easily adjusted according to personalized needs, such as beneficial effects versus adverse effects.”
BackgroundSchmitt, C., Portron, A., Jadidi, S., Sarkar, N., & DiMarchi, R. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13024 · Cited by 74 · cited 2×
“The molecule has also been referred to as MAR709 or RG7697.”
BackgroundThondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
Self-citationGIP and GLP-1 receptor antagonism during a meal in healthy individuals
Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgz175 · Cited by 68 · cited 2×
“32,83,85 As mentioned above, two different once-weekly GIP receptor agonists show diverse results: one (LY3537021) induced body weight reductions and reduced fasting plasma glucose, while the other (NNC0480-0389) did not show an effect on body weight or gly-caemia in patients with type 2 diabetes.”
BackgroundSelf-citationBergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care · doi:10.2337/dc19-0578 · Cited by 62 · cited 3×
“The glucagon levels are thus higher during infusions of GLP-1 + GIP compared with GLP-1 alone, which may result in higher plasma glucose levels.(36,78) Because no long-term studies of GLP-1 and GIP co-administration have been carried out, body weight and cardiovascular outcomes have not been assessed.”
BackgroundResultSelf-citationVadher, K., Patel, H., Mody, R., Levine, J. A., Hoog, M., Cheng, A. Y., Pantalone, K. M., & Sapin, H. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14775 · Cited by 56 · cited 1×
“126,127 Another issue is the relationship between the GLP-1 receptor and GIP receptor activation by the unimolecular co-agonist.”
BackgroundLarsen, A. T., Gydesen, S., Sonne, N., Karsdal, M. A., & Henriksen, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-020-00678-2 · Cited by 33 · cited 1×
“…should be challenged by comparison with other combination approaches (e.g. combinations of GLP-1 and GIP analogues, or GLP-1 and amylin analogues, 132 or GLP-1 analogues and GIP receptor antagonists 58,121,122 ), where the dose ratios could be easily adjusted according to personalized needs,…”
BackgroundKNOP, F. K., URVA, S., RETTIGANTI, M., BENSON, C., ROELL, W., MATHER, K. J., HAUPT, A., & PRATT, E. J. (2023) · Diabetes · doi:10.2337/db23-56-or · Cited by 29 · cited 2×
“68 The molecular details or any other data from the clinical studies with the two GIP receptor agonists have not been disclosed.”
BackgroundSelf-citationPro-inflammatory gene expression profile in obese adults with high plasma GIP levels
Góralska, J., Raźny, U., Polus, A., Stancel-Możwiłło, J., Chojnacka, M., Gruca, A., Zdzienicka, A., Dembińska-Kieć, A., Kieć-Wilk, B., Solnica, B., et al. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.305 · Cited by 22
OLSEN, M. B., HÖVELMANN, U., GRIFFIN, J., KNUDSEN, K. M., ERIKSSON, P.-O., & AGERSNAP, M. A. (2022) · Diabetes · doi:10.2337/db22-335-or · Cited by 10
Research works printed but not linked: 70
- 10.1016/S0140-6736(87)91194-9 · DOI · Paper page
- 10.1210/jc.2003-030738 · DOI · Paper page
- 10.2337/db08-0958 · DOI · Paper page
- 10.1186/s13063-019-3259-x · DOI · Paper page
- 10.1007/s10741-021-10106-9 · DOI
- 10.1016/S2468-1253(22)00198-4 · DOI
- 10.1016/S0140-6736(21)01324-6 · DOI · Paper page
- 10.1016/S0140-6736(21)02188-7 · DOI · Paper page
- 10.1007/s00125-017-4450-9 · DOI · Paper page
- 10.1210/jc.76.4.912 · DOI · Paper page
- 10.1016/0167-0115(94)90136-8 · DOI · Paper page
- 10.1111/j.1365-2265.2008.03451.x · DOI · Paper page
- 10.1152/ajpendo.00665.2010 · DOI · Paper page
- 10.1152/ajpgi.1998.275.5.G984 · DOI · Paper page
- 10.14814/phy2.13102 · DOI
- 10.1210/jc.2013-3766 · DOI · Paper page
- 10.3389/fcell.2021.749607 · DOI · Paper page
- 10.1016/j.bone.2020.115553 · DOI
- 10.1002/jbmr.4308 · DOI
- 10.1530/EC-17-0015 · DOI · Paper page
- 10.2337/db11-1451 · DOI · Paper page
- 10.1016/j.peptides.2019.170224 · DOI · Paper page
- 10.1016/j.peptides.2022.170749 · DOI · Paper page
- 10.1016/j.bcp.2020.114001 · DOI · Paper page
- 10.1016/j.bcp.2018.01.040 · DOI
- 10.1074/jbc.M213179200 · DOI
- 10.1128/MCB.00256-14 · DOI · Paper page
- 10.1111/bph.13323 · DOI · Paper page
- 10.1016/j.cmet.2017.11.003 · DOI
- 10.2337/db21-0848 · DOI · Paper page
- Bergmann NC, 2022, Diabetes, Obesity and Metabolism, 18
- 10.1007/s00125-021-05547-8 · DOI
- 10.1210/clinem/dgac542 · DOI
- NovoNordisk, 2023, Financial Report for 1 January 2023 to 31 March 2023, 1
- 10.2337/db13-1455 · DOI · Paper page
- Stensen S, 2022, Endogenous glucose‐dependent insulinotropic polypeptide contributes to sitagliptin‐mediated improvement in β‐cell function in patients with type 2 diabetes, Diabetes, 71, 2209
- Nauck MA, 1993, Preserved incretin activity of glucagon‐like peptide 1 [7‐36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type‐2 diabetes mellitus, JClinInvest, 91, 301
- 10.2337/diabetes.50.11.2497 · DOI · Paper page
- Hoe B, 2022, Improved glycemic control in patients with type 2 diabetes improves beta cell actions of endogenous glucose‐dependent insulinotropic polypeptide, Diabetes, 71, 1
- Adriaenssens AE, 2020, The glucose‐dependent insulinotropic polypeptide signaling axis in the central nervous system, Peptides, 125, 170
- 10.2337/db13-1627 · DOI · Paper page
- 10.1530/EJE-21-0135 · DOI · Paper page
- 10.1210/jc.2015-3133 · DOI · Paper page
- 10.1016/j.beem.2004.08.007 · DOI
- 10.1111/jgh.13026 · DOI · Paper page
- Kanie T, 2021, Dipeptidyl peptidase‐4 inhibitors, glucagon‐like peptide 1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors for people with cardiovascular disease: a network meta‐analysis, Cochrane Database Syst Rev, 10, 1
- 10.2337/db12-0976 · DOI · Paper page
- 10.1161/HYPERTENSIONAHA.121.17852 · DOI
- 10.1016/j.peptides.2017.12.021 · DOI · Paper page
- Gabe MBN, 2022, GIP and GLP‐2 together improve bone turnover in humans supporting GIPR‐GLP‐2R co‐agonists as future osteoporosis treatment, Pharmacol Res, 176, 1
- EMEA/H/C/005620/0000, 2022, Assessment Report
- 10.2337/db23-127-OR · DOI
- 10.1038/s41401-021-00758-6 · DOI
- Zhao F, 2021, Structural insights into hormone recognition by the human glucose‐dependent insulinotropic polypeptide receptor, Elife, 10, 1
- 10.1073/pnas.2116506119 · DOI · Paper page
- 10.1111/dom.14572 · DOI · Paper page
- 10.1007/s40262-022-01140-3 · DOI · Paper page
- 10.1038/s41467-018-03941-2 · DOI · Paper page
- 10.1172/JCI140046 · DOI · Paper page
- 10.1172/JCI143199 · DOI
- 10.1210/jc.2004-2460 · DOI · Paper page
- 10.3389/fendo.2020.00178 · DOI · Paper page
- 10.1111/dom.13018 · DOI · Paper page
- Amgen, 2022, AMG 133 is a first‐in‐class investigational bispecific molecule that activates GLP‐1R and inhibits GIPR
- 10.1016/j.coph.2020.08.011 · DOI
- 10.1111/bph.13384 · DOI
- 10.1111/dom.14736 · DOI
- 10.1017/S0007114511005228 · DOI
- 10.1016/j.mce.2014.10.025 · DOI
- 10.1210/jc.2019-00008 · DOI · Paper page
Cited by
What is the pipeline for future medications for obesity?
Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2025) · International Journal of Obesity · doi:10.1038/s41366-024-01473-y · Cited by 332
“Nevertheless, a number of other hypotheses have been suggested and both GIP receptor activation and GIP receptor antagonism have been proposed as potential mechanisms to tirzepatide ’ s ef fi cacy [53].”
GLP-1 physiology in obesity and development of incretin-based drugs for chronic weight management
Holst, J. J. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01113-9 · Cited by 125
“The effectiveness of tirzepatide with respect to both its antidiabetic and its anti-obesity actions is impressive and indisputable but contrasts with expectations regarding the contribution of GIP activity to the effects of the co-agonist 166 .”
Self-citationApperloo, E. M., Tuttle, K. R., Pavo, I., Haupt, A., Taylor, R., Wiese, R. J., Hemmingway, A., Cherney, D. Z. I., Sattar, N., & Heerspink, H. J. L. (2025) · Diabetes Care · doi:10.2337/dc24-1773 · Cited by 53
Madsbad, S., & Holst, J. J. (2025) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2025.2472408 · Cited by 43
“The binding to the GIP receptor is comparable to that of native GIP, while the binding affinity for the GLP-1 receptor is five times lower than that of the native hormone [69].”
Self-citationHoffmann, K., Michalak, M., Rizzo, M., Maggio, V., & Paczkowska, A. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2586703 · Cited by 8
“Tirzepatide (Ly3298176) engages both glucose-dependent insu-linotropic polypeptide receptor (GIPR) and GLP-1 receptor (GLP-1 R) simultaneously (dual agonism), enhancing insulin secretion, reducing glucagon levels, and promoting appetite suppression and weight loss [8–11].”
Metadata
- Authors
- Gasbjerg, L. S., Rosenkilde, M. M., Meier, J. J., Holst, J. J., & Knop, F. K.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2023-08-08
- Volume
- 25
- Issue
- 11
- Pages
- 3079-3092
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W4385663314
- Cited by
- 41
- References
- 62
- FWCI
- 6.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.